Abstract
"Angiogenesis-dependent diseases", such as cancer and retinopathies, affect a large number of individuals. In addition to the suffering of these individuals, these diseases cause great socioeconomic impacts. In this context, the pharmaceutical industry has been committed to developing drugs with anti-angiogenic activity, especially with anti-VEGF activity. Although great strides have been…